NCT07512934|Recruiting
Assessment of Pancreatic Dysfunction in Patients With Type 2 Diabetes
T3cDM-AKT
Integrated Assessment of Pancreatic Dysfunction in Patients With Type 2 Diabetes: a Cross-sectional Study Protocol
Loading search results
T3cDM-AKT
Integrated Assessment of Pancreatic Dysfunction in Patients With Type 2 Diabetes: a Cross-sectional Study Protocol
Sponsor study identifier
Secondary identifiers
OTHER_GRANT · West Kazakhstan Marat Ospanov Medical University
observational
310
1 country
1
Study Start
July 7, 2025
Actual (reported)Primary Completion
July 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this observational study is to better understand how the pancreas works in adults with type 2 diabetes. The study focuses on both hormone production (endocrine function) and digestive function (exocrine function) of the pancreas. The main questions it aims to answer are:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 7, 2025
Actual (reported)March 25, 2026
Actual (reported)April 6, 2026
Actual (reported)July 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Prevalence of pancreatogenic diabetes
Proportion of participants with type 2 diabetes mellitus meeting predefined criteria of pancreatogenic diabetes based on integrated assessment of pancreatic function (fecal elastase-1, pancreatic ultrasound findings, absence of autoimmune markers, and impaired β-cell function).
At single study visit (baseline)
Fecal elastase-1
Baseline (single study visit)
Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q)
Baseline (single study visit)
Adults with type 2 diabetes mellitus classified as not having exocrine pancreatic insufficiency according to fecal elastase-1 levels.
Adults with type 2 diabetes mellitus classified as not having exocrine pancreatic insufficiency according to Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q) results.
kazakh population
Outpatient clinics of Aktobe region, West Kazakhstan Marat Ospanov Medical University
Aktobe, Aktobe, 030019, Kazakhstan
First Submitted
March 25, 2026
First Posted
April 6, 2026
Study Start
July 7, 2025
Actual (reported)Primary Completion
July 1, 2026
Estimated (date passed)Patients With Type 2 Diabetes
C-peptide
Baseline (single study visit)
Glycated hemoglobin (HbA1c)
Baseline (single study visit)
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Baseline (single study visit)
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
April 6, 2026
Record last verified: 2026-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: